Clinical Trial

Pharmacokinetics of Y-4 Tablets With Pregabalin Capsules and Riluzole Tablets in Chinese Healthy Subject

Recruiting Phase 1
View on ClinicalTrials.gov →
Record status
This record was last updated April 20, 2025 (before its estimated May 2025 completion). Its status may not reflect the trial's current state.
Summary
Y-4 is a new fixed-dose combination drug product containing two active ingredients of pregabalin and riluzole. The objective of the trial is to compare pharmacokinetic characteristics of Y-4 tablets with pregabalin capsules (Lyrica®) and riluzole tablets (Rilutek®) in Chinese healthy adult subjects after single oral administration under fasted condition.
Trial Details
NCT Number NCT06935721
Lead Sponsor Beijing Tiantan Hospital
Collaborators: Neurodawn Pharmaceutical Co., Ltd.
Conditions Healthy Male and Female Subjects
Enrollment 10 participants
Start Date 2025-03-28
Primary Completion 2025-05 (estimated)
Study Completion 2025-06 (estimated)
Updated on ClinicalTrials.gov 2025-04-20